Objective     To study the pharmacokinetics and relative bioavailability of pyridostigmine bromide sustained-release tablets and conventional tablets in rabbits.     Methods     Six New Zealand rabbits were randomly and evenly divided into two groups. Based on the self-crossover control experiment

the rabbits were subjected to single-dose oral administration of pyridostigmine bromide sustained-release tablets and conventional tablets. The pyridostigmine bromide concentrations in the plasma of rabbits were measured by high-performance liquid chromatography

based on which the pharmacokinetic parameters and relative bioavailability were calculated.     Results

     After delivery

pyridostigmine bromide sustained-release tablets and conventional tablets had the following pharmacokinetic parameters: t

max

= 2 h and 4 h; C

max

= 17.944 0.991 mg/L and 15.442±0.215 mg/L; AUC

0-∞

= 201.956±4.623 mg/(h·L) and 200.557±3.357 mg/(h·L). When compared with conventional tablets

sustained-release tablets had relative bioavailability of 102.89%.     Conclusion     Pyridostigmine bromide sustained-release tablets have an obvious sustained-release effect

and are bioequivalent to conventional tablets.